Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 1
2006 2
2007 3
2008 5
2009 6
2010 3
2011 10
2012 4
2013 9
2014 4
2015 5
2016 14
2017 12
2018 19
2019 12
2020 7
2021 9
2022 8
2023 11
2024 6
2025 16
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers.
Miao EA, Yeap B, Daher S, Lomibao M, Sun F, Keogh R, Lambden J, Reyes A, Peterson JL, Liang J, Liu A, Do A, Lee C, Hsu M, Evangelist M, Reuss J, Gadgeel SM, Lee M, Patil T, Lam V, Neal JW, Drilon A, Lin JJ. Miao EA, et al. Among authors: gadgeel sm. JCO Precis Oncol. 2026 Mar;10(3):e2501148. doi: 10.1200/PO-25-01148. Epub 2026 Mar 30. JCO Precis Oncol. 2026. PMID: 41911514
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Besse B, Subbiah V, Curigliano G, Bowles DW, Doebele RC, Mansfield AS, Baik CS, de Lima Lopes G, Paz-Ares L, Taylor MH, Tan DSW, Alonso G, Gadgeel SM, Kalemkerian GP, Ou SI, van der Wekken AJ, Becerra CR, Evangelist M, Griesinger F, Liu SV, Lou Y, Mazières J, Melear JM, Narang M, Saxena A, Thomas M, Wang S, Thomassen A, Lee DH, Kim DW, Gainor JF. Besse B, et al. Among authors: gadgeel sm. J Clin Oncol. 2026 Mar 26:JCO2501489. doi: 10.1200/JCO-25-01489. Online ahead of print. J Clin Oncol. 2026. PMID: 41886723
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions.
Patil T, Lin JJ, Cheema PK, Carrizosa DR, Burkard ME, Elamin YY, Desai J, Patel JD, Nagasaka M, Reckamp KL, Waqar SN, Bauman JR, Schram AM, Gadgeel SM, Ma PC, Konduri K, Nguyen D, Misleh J, Bleeker J, Weiss M, Thavaneswaran S, Haura EB, Deegan M, Kaufman J, Srivastava J, Jansen VM, Liu SV. Patil T, et al. Among authors: gadgeel sm. JCO Precis Oncol. 2025 Aug;9:e2500221. doi: 10.1200/PO-25-00221. Epub 2025 Dec 22. JCO Precis Oncol. 2025. PMID: 41428976 Free PMC article. Clinical Trial.
Pembrolizumab in Combination With Platinum-Based Chemotherapy in Patients With Recurrent EGFR and ALK Gene Altered Non-Small-Cell Lung Cancer (NSCLC).
Gadgeel SM, Nagasaka M, Dziubek K, Braun T, Hassan K, Cheng H, Halmos B, Wozniak A, Stevenson J, Patil P, Pennell N, Fidler MJ, Qin A, Niu Z, Nagrath S, Kalemkerian GP. Gadgeel SM, et al. Clin Lung Cancer. 2026 Mar;27(2):189-196.e1. doi: 10.1016/j.cllc.2025.09.002. Epub 2025 Oct 3. Clin Lung Cancer. 2026. PMID: 41046186 Clinical Trial.
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
Yang JC, Lu S, Hayashi H, Felip E, Spira AI, Girard N, Kim YJ, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Passaro A, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Kim SW, Gadgeel SM, Owen S, Xie J, Sun T, Mehta J, Venkatasubramanian R, Ennis M, Fennema E, Daksh M, Roshak A, Man J, Knoblauch RE, Bauml JM, Baig M, Shah S, Sethi S, Cho BC; MARIPOSA Investigators. Yang JC, et al. Among authors: gadgeel sm. N Engl J Med. 2025 Oct 30;393(17):1681-1693. doi: 10.1056/NEJMoa2503001. Epub 2025 Sep 7. N Engl J Med. 2025. PMID: 40923797 Clinical Trial.
Is Shorter Better in Oncology Patients, Too? A Retrospective Cohort Study of Short- Versus Long-Course Antibiotic Therapy for Uncomplicated Infections in Solid Tumor Patients Receiving Care in Ambulatory Oncology Clinics.
Arena CJ, El-Tatari B, Lovric K, Greenlee SB, Kenney RM, Gadgeel SM, Patterson K, Shallal AB, Alangaden GJ, Davis SL, Veve MP. Arena CJ, et al. Among authors: gadgeel sm. Open Forum Infect Dis. 2025 Aug 21;12(9):ofaf505. doi: 10.1093/ofid/ofaf505. eCollection 2025 Sep. Open Forum Infect Dis. 2025. PMID: 40908971 Free PMC article.
Resistance mechanisms in anaplastic lymphoma kinase-positive lung cancer.
Behinaein P, Gadgeel SM, Rattan R, MacKeigan JP, Pilling A, Rous FA, Martin KR, Okereke IC. Behinaein P, et al. Among authors: gadgeel sm. Crit Rev Oncol Hematol. 2025 Oct;214:104821. doi: 10.1016/j.critrevonc.2025.104821. Epub 2025 Jun 27. Crit Rev Oncol Hematol. 2025. PMID: 40581545 Review.
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.
Ruan DY, Wu HX, Xu Y, Munster PN, Deng Y, Richardson G, Yan D, Lee MA, Lee KW, Pan H, Hager S, Li X, Wei S, Hou X, Underhill C, Millward M, Nordman I, Zhang J, Shan J, Han G, Grewal J, Gadgeel SM, Sanborn RE, Huh SJ, Hu X, Zhang Y, Xiang Z, Luo L, Xie X, Shi Z, Wang Y, Zhang L, Wang F, Xu RH. Ruan DY, et al. Among authors: gadgeel sm. Signal Transduct Target Ther. 2025 Jun 17;10(1):189. doi: 10.1038/s41392-025-02274-z. Signal Transduct Target Ther. 2025. PMID: 40523897 Free PMC article. Clinical Trial.
154 results